首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   1345584篇
  免费   86222篇
  国内免费   2517篇
耳鼻咽喉   19217篇
儿科学   44708篇
妇产科学   35995篇
基础医学   191817篇
口腔科学   37529篇
临床医学   116674篇
内科学   254278篇
皮肤病学   31864篇
神经病学   105258篇
特种医学   55121篇
外国民族医学   254篇
外科学   206631篇
综合类   24852篇
现状与发展   1篇
一般理论   345篇
预防医学   89522篇
眼科学   31555篇
药学   105363篇
  10篇
中国医学   3630篇
肿瘤学   79699篇
  2021年   10160篇
  2019年   10334篇
  2018年   15877篇
  2017年   12557篇
  2016年   14662篇
  2015年   16293篇
  2014年   20919篇
  2013年   30724篇
  2012年   43704篇
  2011年   45803篇
  2010年   26444篇
  2009年   23835篇
  2008年   42386篇
  2007年   45806篇
  2006年   46280篇
  2005年   45042篇
  2004年   42821篇
  2003年   41259篇
  2002年   39800篇
  2001年   70065篇
  2000年   71384篇
  1999年   59333篇
  1998年   15045篇
  1997年   13339篇
  1996年   12932篇
  1995年   12034篇
  1994年   10898篇
  1993年   10355篇
  1992年   42518篇
  1991年   40765篇
  1990年   40164篇
  1989年   38479篇
  1988年   34537篇
  1987年   33689篇
  1986年   31731篇
  1985年   29774篇
  1984年   21707篇
  1983年   18164篇
  1982年   10164篇
  1979年   19507篇
  1978年   13249篇
  1977年   11761篇
  1976年   10184篇
  1975年   11794篇
  1974年   13465篇
  1973年   13008篇
  1972年   12371篇
  1971年   11617篇
  1970年   10612篇
  1969年   10231篇
排序方式: 共有10000条查询结果,搜索用时 296 毫秒
1.
2.
Quality of Life Research - The COVID-19 pandemic might add to the stressors experienced by people living with rheumatic diseases. This study aimed to examine rheumatic patients’ functional...  相似文献   
3.
Molnár  B.  Aroca  S.  Dobos  A.  Orbán  K.  Szabó  J.  Windisch  P.  Stähli  A.  Sculean  A. 《Clinical oral investigations》2022,26(12):7135-7142
Clinical Oral Investigations - To evaluate t he long-term outcomes following treatment of RT 1 multiple adjacent gingival recessions (MAGR) using the modified coronally advanced tunnel (MCAT) with...  相似文献   
4.
Intratumor heterogeneity is a main cause of the dismal prognosis of glioblastoma (GBM). Yet, there remains a lack of a uniform assessment of the degree of heterogeneity. With a multiscale approach, we addressed the hypothesis that intratumor heterogeneity exists on different levels comprising traditional regional analyses, but also innovative methods including computer-assisted analysis of tumor morphology combined with epigenomic data. With this aim, 157 biopsies of 37 patients with therapy-naive IDH-wildtype GBM were analyzed regarding the intratumor variance of protein expression of glial marker GFAP, microglia marker Iba1 and proliferation marker Mib1. Hematoxylin and eosin stained slides were evaluated for tumor vascularization. For the estimation of pixel intensity and nuclear profiling, automated analysis was used. Additionally, DNA methylation profiling was conducted separately for the single biopsies. Scoring systems were established to integrate several parameters into one score for the four examined modalities of heterogeneity (regional, cellular, pixel-level and epigenomic). As a result, we could show that heterogeneity was detected in all four modalities. Furthermore, for the regional, cellular and epigenomic level, we confirmed the results of earlier studies stating that a higher degree of heterogeneity is associated with poorer overall survival. To integrate all modalities into one score, we designed a predictor of longer survival, which showed a highly significant separation regarding the OS. In conclusion, multiscale intratumor heterogeneity exists in glioblastoma and its degree has an impact on overall survival. In future studies, the implementation of a broadly feasible heterogeneity index should be considered.  相似文献   
5.
6.
7.
8.
9.
10.
Inflammatory bowel disease (IBD) is a chronic disease that requires chronic treatment throughout the evolution of the disease, with a complex physiopathology that entails great challenges for the development of new and specific treatments for ulcerative colitis and Crohn´s disease. The anti-tumor necrosis factor alpha therapy has impacted the clinical course of IBD in those patients who do not respond to conventional treatment, so there is a need to develop new therapies and markers of treatment response. Various pathways involved in the development of the disease are known and the new therapies have focused on blocking the inflammatory process at the gastrointestinal level by oral, intravenous, subcutaneous, and topical route. All these new therapies can lead to more personalized treatments with higher success rates and fewer relapses. These treatments have not only focused on clinical remission, but also on achieving macroscopic changes at the endoscopic level and microscopic changes by achieving mucosal healing. These treatments are mainly based on modifying signaling pathways, by blocking receptors or ligands, reducing cell migration and maintaining the integrity of the epithelial barrier. Therefore, this review presents the efficacy and safety of the new treatments that are currently under study and the advances that have been made in this area in recent years.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号